| Date |
Subject |
Media |
| 2025-08-12 |
CRDMO National Team’s New Factory to Mass Produce 13 Million mRNA Vaccine Doses Annually
|
The government-initiated CRDMO (Contract Research, Development, and Manufacturing Organization) national team—Taiwan Bio-Manufacturing Corporation (TBMC)—announced on the 25th that its GMP facility in Zhubei is expected to be completed by the end of this year. The factory will undergo validation in the first quarter of next year and begin production in the second quarter, with an annual capacity of 13 million mRNA vaccine doses. This supports the government’s “National Security Vaccine Resilience” plan and aims to establish Asia’s most advanced nucleic acid drug manufacturing hub. |
| 2025-08-12 |
BioPhoenix Secures U.S. Up Therapeutics License to Develop Novel Proteasome Inhibitor Against Cancer
|
BioPhoenix, a subsidiary of San Fu Chemical’s San Fu Biotech, announced on the 24th that it has signed a licensing agreement with U.S.-based innovative drug developer Up Therapeutics. BioPhoenix has acquired global development, manufacturing, and commercialization rights for Up284, a first-in-class small molecule drug targeting solid tumors such as ovarian cancer. Both parties plan to submit an IND application and initiate Phase 1 clinical trials within the next 18 months. |
| 2025-08-12 |
Asia Pathogenomics Expands into Japan, Marking Global Milestone for Taiwan’s Leading Infectious Disease Diagnostics Company
|
Asia Pathogenomics Co., Ltd. has officially established a Japanese subsidiary, APGアジア準訳ジャパン株式会社, in Tokyo as a key stepping stone for its expansion into the broader Asian market. The move aims to bring the company closer to Japan’s clinical needs while accelerating the application of metagenomic next-generation sequencing (mNGS) in infectious disease diagnostics, and deepening partnerships across both the medical and industrial sectors. |
| 2025-08-12 |
CH BIOTECH R&D Secures NT$1.2 Billion Order as New Product Heads to Indonesia
|
CH BIOTECH R&D, a leading agricultural biotechnology company, announced yesterday the global launch of its next-generation product, “Endurance Enhancer.” The company also signed a distribution agreement worth USD 42 million (approximately NT$1.2 billion) with its Indonesian partner, PT MAJU MAKMUR UTOMO (M2U). The product is expected to begin contributing to revenue starting in August. |
| 2025-08-12 |
Inventec’s Smart Healthcare Arm GOOD FUTURE BIOMEDICAL Reports Strong Progress
|
Inventec has been actively expanding into high-margin product lines such as smart healthcare in recent years. Its subsidiary, GOOD FUTURE BIOMEDICAL, has secured a firm foothold in the smart health and medical market. The company’s flagship product—its circulating tumor cell (CTC) detection system—is now being promoted in partnership with Malaysian firm Wellspring Solutions Sdn Bhd, aiming to obtain Malaysia’s Medical Device Authority (MDA) registration. Certification is expected within the year, which will further strengthen collaborations with local healthcare institutions. |
| 2025-08-11 |
Bora Pharmaceuticals Strengthens U.S. Supply Chain as Iowa Governor Visits Operations
|
Bora Pharmaceuticals announced on the 23rd that Iowa Governor Kim Reynolds successfully led a delegation to visit its manufacturing site in Maple Grove, Minnesota, as well as its U.S. pharmaceutical sales subsidiary, Upsher-Smith Laboratories. During the visit, the governor participated in a roundtable discussion and toured the facilities, focusing on the theme of “localizing pharmaceutical manufacturing” and regional supply chain integration in the U.S. Midwest. |
| 2025-08-11 |
Chi Mei Hospital Leads in Healthcare Quality with ISO 7101 Certification
|
Amid the challenges posed by an aging population, rising chronic diseases, and accelerating digital transformation, healthcare quality management is facing unprecedented pressures. Once again taking the lead in medical innovation, Chi Mei Medical Center, operated by the Chi Mei Medical Foundation, officially obtained ISO 7101 certification—the world’s first international standard dedicated to healthcare quality management—in July this year. It is now the first medical center in Taiwan to achieve this milestone, marking a new chapter in aligning Taiwan’s healthcare quality with international standards. |
| 2025-08-11 |
Taipei Veterans General Hospital’s Electronic Medical Record System Achieves U.S. Certification
|
On July 11, Taipei Veterans General Hospital (TVGH) officially passed the Stage 6 certification of the Electronic Medical Record Adoption Model (EMRAM) developed by the Healthcare Information and Management Systems Society (HIMSS). This milestone reflects the hospital’s attainment of globally advanced standards in key areas such as EMR system functionality, clinical decision support, and information security—demonstrating TVGH’s strong capabilities and tangible achievements in the realm of smart healthcare. |
| 2025-08-11 |
AlleyPin Partners with Global Pharma Data Leader IQVIA to Accelerate Digital Health Transformation in Taiwan Clinics
|
AlleyPin has officially announced a strategic partnership with IQVIA, a global leader in pharmaceutical data and technology services. The two companies will jointly promote clinic-centric digital health innovation, introducing forward-looking data applications and tech-enabled service models to Taiwan’s primary care sector. |
| 2025-08-11 |
Syncell Inc. Raises NT$750 Million in Series A Funding to Build Taiwan’s International-Class Biotech High-End Instrument Brand
|
Taiwan innovative biotech instrument company Syncell Inc. today announced the successful completion of a NT$750 million Series A funding round, led by Taiwania Capital. The round also saw participation from heavyweight investors including Everbright Biofund, National Development Fund, Abico Group, Himalaya Venture Fund, Ta Ya Venture Capital, BE Health, Isaiah Capital, Hua Nan Venture Capital, First Venture Capital, Dongan Investment, ITIC, and Taiwan Cooperative Venture Capital. The capital raised will be used to accelerate international market expansion and technology development, positioning Syncell as a leading Taiwanese biotech company creating internationally recognized high-end instruments. |
